In a trial involving 255 patients with moderate-to-severe plaque psoriasis, the oral interleukin-23–receptor antagonist peptide JNJ-77242113 showed a dose–response relationship and greater efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results